The Effect of STW5 (Iberogast) on Reflux Symptoms in Patients With Concurrent Dyspeptic Symptoms: A Double-blind Randomized Placebo-controlled Crossover Trial.

Renske A B Oude NijhuisThijs KuipersJac M OorsThomas V K HerregodsBoudewijn F KessingJeroen M SchuitenmakerAndreas J P M SmoutAlbert J Bredenoord

Published in: Journal of neurogastroenterology and motility (2023)

We found some indications pointing towards a beneficial effect of STW5 on reflux symptoms in dyspeptic patients, with reduction of esophageal hypersensitivity as a potential underlying mechanism. Our findings will have to be confirmed in larger studies.

Keyphrases

placebo controlled
double blind
phase iii
phase ii
open label
study protocol
clinical trial
sleep quality
phase ii study
drug induced
risk assessment
human health